SOPHiA GENETICS SA (SOPH) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, SOPHiA GENETICS SA's filing signal turned negative.

SOPHiA GENETICS SA is a cloud-native software technology company focused on establishing data-driven medicine as the standard of care. Its proprietary SOPHiA DDM Platform analyzes complex multimodal health data, including genomics and radiomics, to generate clinically actionable insights for oncology, rare diseases, and other areas. The company operates a decentralized model, pushing analytics solutions to customer sites globally, enabling knowledge sharing and collective intelligence. As of December 31, 2025, SOPHiA GENETICS served over 993 hospital, laboratory, and biopharma customers across 75 countries, analyzing approximately 2.3 million genomic profiles. Its platform is utilized by healthcare providers, research laboratories, and biopharmaceutical companies for precision medicine applications.

Revenue is primarily generated from the use of its SOPHiA DDM Platform, including pay-per-use analyses, software licenses for its Alamut suite, and sales of bundled instruments and consumables. Revenue is also derived from services provided to biopharmaceutical customers for custom analyses and access to its database for clinical trials and research projects.